Cereus savings—successful use of dalbavancin in an immunocompromised patient with Bacillus cereus bacteremia
ASM Case Reports · 03.11.2026 · 2 (6)
DOI: 10.1128/asmcr.00024-26 ↗Kurz gefasst
Fallbericht in der Zeitschrift ASM Case Reports, erschienen am 03.11.2026. Verfasst von Daisy L Eaton und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, SSM Health DePaul Hospital, Bridgeton, Missouri, USA. Die Arbeit nennt 11 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Dalbavancin’s pharmacokinetics (long half-life, high tissue penetration, once-weekly dosing) make it an attractive alternative for patients with barriers to outpatient parenteral antimicrobial therapy or at risk for line-related complications. In this case, we used dalbavancin to promote timely discharge for an immunocompromised patient who experienced Bacillus cereus bacteremia due to a peripherally inserted central catheter (PICC) line-associated infection. Although B. cereus is known to cause line-related infections, we present a novel clinical case highlighting the successful use of dalbavancin in an immunocompromised patient with B. cereus bacteremia, and this approach also facilitated earlier discharge. Case Summary A 58-year-old woman with invasive ductal breast cancer on chemotherapy (docetaxel, carboplatin, trastuzumab, pertuzumab), mechanical aortic valve replacement, and other comorbidities presented with febrile neutropenia 2 weeks after her fifth chemotherapy cycle. A month prior, she had completed vancomycin for a suspected port infection. Admission laboratory values revealed pancytopenia (white blood cell count [WBC] 1.7 × 10⁹/L, absolute neutrophil count [ANC] 0.53 × 10⁹/L, hemoglobin 7.8 g/dL, and platelets 51 × 10⁹/L). Both sets of blood cultures obtained prior to empiric vancomycin grew B. cereus , with positive cultures throughout day 3 despite treatment. A transthoracic and transesophageal echocardiography excluded endocarditis. The PICC line was removed on day 2; blood cultures cleared by day 5, and neutropenia resolved on day 7. Given two prior catheter-related infections and logistical challenges with weekend discharge planning, the patient received a single 1,500 mg dose of intravenous dalbavancin rather than receiving a new line and continuing prolonged intravenous therapy. This facilitated discharge 4 days earlier than anticipated. At 2.5-week follow-up and visits at 30, 60, and 90 days, the patient remained clinically well without recurrence of infection.
Conclusion
This case highlights successful off-label use of dalbavancin in a complex case, suggesting that its use in such cases warrants further studies, especially when standard regimens can be logistically challenging.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmacy, SSM Health DePaul Hospital, Bridgeton, Missouri, USA.
- Division of Infectious Diseases, Allergy and Immunology, SSM Health Saint Louis University Hospital, St. Louis, Missouri, USA.
- Department of Pathology, SSM Health, Saint Louis University, St. Louis, Missouri, USA.
ORCID-Profile: Daisy L Eaton, Matthew Stack, Hunter O Rondeau
Zitieren
APA
Eaton, D. L., Stack, M., Chamberland, R., & Rondeau, H. O. (2026). Cereus savings—successful use of dalbavancin in an immunocompromised patient with Bacillus cereus bacteremia. ASM Case Reports, 2(6). https://doi.org/10.1128/asmcr.00024-26
Vancouver
Eaton DL, Stack M, Chamberland R, Rondeau HO. Cereus savings—successful use of dalbavancin in an immunocompromised patient with Bacillus cereus bacteremia. ASM Case Reports. 2026;2(6). doi:10.1128/asmcr.00024-26
BibTeX
@article{Eaton2026,
author = {Eaton, Daisy L and Stack, Matthew and Chamberland, Robin and Rondeau, Hunter O},
title = {Cereus savings—successful use of dalbavancin in an immunocompromised patient with Bacillus cereus bacteremia},
journal = {ASM Case Reports},
year = {2026},
volume = {2},
number = {6},
doi = {10.1128/asmcr.00024-26}
}
EUVIMED